港交所：2月16日，贝莱德持有的药明生物H股多头头寸从5.22%降至4.51%。

Group 1 - The core point of the article is that BlackRock's long position in WuXi Biologics H shares has decreased from 5.22% to 4.51% as of February 16 [1]